Docoh
Loading...

PRPO Precipio

Filed: 21 Mar 04, 7:00pm
                                                                    Exhibit 99.1

        Transgenomic to Provide Manufacturing Support for Development of
                      Novel Regulatable Anticoagulant Drug


      Partnering with Regado Biosciences to Advance Synthetic Nucleic Acid
                        Drug-Antidote Pair Toward Clinic


    OMAHA, Neb., March 22  /PRNewswire-FirstCall/ -- Transgenomic Inc.
(Nasdaq: TBIO) announced today that it has signed a contract with North
Carolina-based Regado Biosciences to manufacture the two components of an
antidote-controlled, regulatable anticoagulant therapy.  Transgenomic will
also provide a range of related services, including analytical method
development, stability studies and other related formulation development
activities, in support of Regado's advance toward an investigational new drug
(IND) filing.  Oligonucleotide manufacturing and related development work will
be completed at the Company's facility in Boulder, Colo.  Some of the chemical
building blocks that serve as raw materials in synthetic DNA and/or RNA
manufacture will be supplied by Transgenomic's plant in Glasgow, Scotland, for
this and future work.

    Regado has developed antidote-controlled aptamer technology, allowing the
reversal of an aptamer's therapeutic activity.  Regado's development-stage
anticoagulant therapy consists of an RNA-based aptamer, which inhibits the
therapeutic target, and a synthetic oligonucleotide, which binds the aptamer
and functions as the "antidote."  Appropriately timed use of the two molecules
in combination represents a novel approach aimed at reducing potential
complications associated with antithrombotic therapies.  This technology, as
described in the journal Nature (Rusconi et al. 2002. Nature 419: 90-94), has
been shown to reverse the anti-clotting activity of Regado's lead
anticoagulant aptamer in both cellular and animal models.

    "We are delighted to have the opportunity to partner with Regado in their
efforts to move their innovative regulatable drug-antidote technology toward
the clinic," said Collin D'Silva, Transgenomic's CEO.  "Regado is the type of
customer likely to reap maximum benefit from our position as a
vertically-integrated supplier of nucleic acids products and value-added
services.  Our combined offerings provide a comprehensive solution to support
the transition from research to production-scale cGMP manufacturing and enable
progression through the clinical development process."

    Doug Gooding, CEO of Regado Biosciences, commented that Transgenomic's
synthetic nucleic acid manufacturing and development expertise is a valuable
asset in Regado's clinical development efforts.  "Our RNA-based lead drug
candidate requires both the incorporation of non-standard nucleic acid
building blocks, as well as other chemical modifications.  We believe
Transgenomic will prove to be a valued partner in this development process, as
the company possesses a significant proportion of what is currently a limited
pool of experience and expertise in this area.  Their activities on our behalf
will allow us to focus our energies on our clinical trials strategy and
continuing the evolution of our technology platform."


    About Regado

    Regado Biosciences is an early-stage biopharmaceutical company positioned
to become a world leader in the discovery, development and commercialization
of antidote-controlled therapeutics.  Its proprietary technology allows Regado
to generate highly specific antidotes for each new drug it develops.  The
rational design of drug-antidote pairs represents a new paradigm for
developing safer therapeutics that address multi-billion dollar markets in
acute care medicine.  The initial focus of the Company is on developing
antidote-controlled drugs that prevent or eliminate blood clots
("antithrombotics").

    For more information, please contact Doug Gooding at 919-949-2990.


    About Transgenomic

    Transgenomic provides versatile and innovative research tools and related
consumable products to the life sciences industry for the synthesis,
separation, analysis and purification of nucleic acids and a wide variety of
nucleic acid-based specialty chemicals.  Transgenomic's BioSystems segment
offers its WAVE(R) Systems and associated consumables.  These systems are
specifically designed for use in genetic variation detection and single- and
double-strand DNA/RNA analysis and purification.  These systems have broad
applicability to genetic research and molecular diagnostics.  To date there
have been over one thousand systems installed in over 30 countries around the
world.  In addition, the BioSystems segment offers WAVE-based biomarker
discovery and validation services in support of translational research,
pre-clinical and clinical studies.

    Through its nucleic acids business segment, Transgenomic provides
specialty chemicals, including advanced nucleic acid building blocks and
associated reagents, used in applications such as genetic diagnostics and
therapeutics, as well as a comprehensive menu of services, including nucleic
acid chemistry R&D, process development, analytical methods development, cGMP
oligonucleotide manufacturing, quality control and regulatory support.

    For more information about the innovative genomics research tools
developed and marketed by Transgenomic, please visit the Company's Web site at
www.transgenomic.com.


    Cautionary Statement

    Certain statements in this press release constitute "forward-looking
statements" of Transgenomic within the meaning of the Private Securities
Litigation Reform Act of 1995, which involve known and unknown risks,
uncertainties and other factors that may cause our actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements.  Forward-looking statements include,
but are not limited to, those with respect to supporting the transition of
drug candidates from research to production-scale cGMP manufacturing and
enabling progression through the clinical development process.  The known
risks, uncertainties and other factors affecting these forward-looking
statements are described from time to time in Transgenomic's reports to the
Securities and Exchange Commission.  Any change in such factors, risks and
uncertainties may cause the actual results, events and performance to differ
materially from those referred to in such statements.  Accordingly, the
company claims the protection of the safe harbor for forward-looking
statements contained in the Private Securities Litigation Reform Act of 1995
with respect to all statements contained in this press release.  All
information in this press release is as of the date of the release and
Transgenomic does not undertake any duty to update this information, including
any forward-looking statements, unless required by law.


    For confirmation of release or further information contact:

     Transgenomic:
     Mitchell L. Murphy            Robert J. Pogulis, Ph.D.
     Transgenomic Inc.             Transgenomic Inc.
     402-452-5418                  845-782-9617
     mmurphy@transgenomic.com      rpogulis@transgenomic.com

     Regado Biosciences
     Doug Gooding
     Regado Biosciences
     919-949-2990


SOURCE  Transgenomic Inc.
    -0-                             03/22/2004
    /CONTACT:  Mitchell L. Murphy, +1-402-452-5418, mmurphy@transgenomic.com,
or Robert J. Pogulis, Ph.D., +1-845-782-9617, rpogulis@transgenomic.com, both
of Transgenomic Inc.; or Doug Gooding of Regado Biosciences, +1-919-949-2990/
    /Web site:  http://www.transgenomic.com /
    (TBIO)

CO:  Transgenomic Inc.; Regado Biosciences
ST:  Nebraska, North Carolina, Scotland, Colorado
IN:  HEA MTC BIO
SU:  PDT CON